Patents by Inventor John C. Timmer

John C. Timmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NKp46-Binding Polypeptides and Uses Thereof
    Publication number: 20250136681
    Abstract: Provided herein are VHH-containing polypeptides that bind NKp46. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 29, 2022
    Publication date: May 1, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Brendan P. Eckelman, Rajay A. Pandit, William Crago, Florian Sulzmaier, Heather Kinkead, Nadja Kern
  • Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20250109203
    Abstract: Provided herein are polypeptides comprising at least one VHH domain that binds ?? TCR and a modified IL-2. Uses of the polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: April 3, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman
  • MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME
    Publication number: 20250092137
    Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 4, 2024
    Publication date: March 20, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, Kyle S. JONES, Rajay A. PANDIT, John C. TIMMER
  • Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
    Publication number: 20250066477
    Abstract: Provided herein are VHH-containing polypeptides that bind ?? T-cells. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 27, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman
  • CD33-Binding Polypeptides and Uses Thereof
    Publication number: 20250059279
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 20, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 12227584
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: February 18, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
    Patent number: 12195533
    Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 14, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, Kyle S. Jones, Rajay A. Pandit, John C. Timmer
  • CLEC12a Binding Polypeptides and Uses Thereof
    Publication number: 20250011436
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: June 20, 2024
    Publication date: January 9, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20250011394
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: March 13, 2024
    Publication date: January 9, 2025
    Applicant: Sanofi AATD Inc.
    Inventors: Brendan P. ECKELMAN, John C. TIMMER, Peter L. NGUY, Grant B. GUENTHER, Quinn DEVERAUX
  • Multivalent and multispecific 41BB-binding proteins
    Patent number: 12187804
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: January 7, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • OX40-Binding Polypeptides and Uses Thereof
    Publication number: 20240409651
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 8, 2024
    Publication date: December 12, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multivalent and Multispecific DR5-Binding Fusion Proteins
    Publication number: 20240376220
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Application
    Filed: April 4, 2024
    Publication date: November 14, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20240376198
    Abstract: Provided herein are NKp46-targeted modified IL-2 polypeptides. Uses of the polypeptides are also provided.
    Type: Application
    Filed: August 29, 2022
    Publication date: November 14, 2024
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, Brendan P. Eckelman, Rajay A. Pandit, William Crago, Florian Sulzmaier, Heather Kinkead, Nadja Kern
  • PD-1 Single Domain Antibodies and Therapeutic Compositions Thereof
    Publication number: 20240317860
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: February 28, 2024
    Publication date: September 26, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • CD33-binding polypeptides and uses thereof
    Patent number: 12084502
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: September 10, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • CLEC12a binding polypeptides and uses thereof
    Patent number: 12043667
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 23, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • OX40-binding polypeptides and uses thereof
    Patent number: 12012459
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: June 18, 2024
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
    Patent number: 11976126
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: May 7, 2024
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Serpin fusion polypeptides and methods of use thereof
    Patent number: 11965017
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: April 23, 2024
    Assignee: InhibRx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • PD-1 single domain antibodies and therapeutic compositions thereof
    Patent number: 11945869
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: April 2, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman